Dr Yuma Yamada, from Faculty of Pharmaceutical Sciences, Hokkaido, Japan will give a talk about Development of nanotechnology to deliver bioactive molecules to mitochondria

As presented by Dr Yuma Yamada, from Faculty of Pharmaceutical Sciences, Hokkaido, Japan:  "Mitochondria are the principal producers of energy in higher cells. Mitochondrial dysfunction is implicated in a variety of human diseases, including cancer and neurodegenerative disorders. Effective medical therapies for such diseases will ultimately require targeted delivery of therapeutic proteins or nucleic acids to the mitochondria, which will be achieved through innovations in the nanotechnology of intracellular trafficking. We have developed a liposome-based nano carrier that delivers its macromolecular cargos to the mitochondria. These liposome particles, which we call MITO-Porters, could achieve mitochondrial delivery independent of size and physical property of the cargo. Furthermore, we are studying about mitochondrial gene therapy. Our ultimate goal is to develop mitochondrial therapy and diagnosis to the point where therapeutic agents function on the mitochondrial genome with experts in the field of mitochondria."

To know more about Development of nanotechnology to deliver bioactive molecules to mitochondria and complete program of the 3rd World Congress on Targeting Mitochondria which will be held in Berlin in November 8-9, 2012, please visit www.targeting-mitochondria.com